EBV抗原発現調節による、EBV関連胃癌に対する効果的ながん免疫療法の開発

通过调节 EBV 抗原表达开发针对 EBV 相关胃癌的有效癌症免疫疗法

• 批准号: 22KF0193
• 负责人: 本庶 佑
• 金额: $ 1.47万
• 依托单位: Kyoto University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for JSPS Fellows
• 财政年份: 2023
• 资助国家: 日本
• 起止时间: 2023-03-08 至 2024-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22KF0193/
• 关键词: scRNA-Seq; NK; EGFR; NSCLC

We collected 12 NSCLC patient samples of PBMC and tumor-infiltrating lymphocytes (TIL) to perform scRNA-Seq. From the result of TIL, we found that the proportion of total NK cells in the patients with EGFR-Mut is larger than that in the WT patients. However, the proportion of uNK (a suset of NK cells) in EGFR-WT patients is larger that in EGFR-Mut patients. We further establish a set of uNK signature genes which is positively associated with the expression of activation markers in CD8T cells. When studying the scRNA-Seq data of the patients PBMC, the NK cells express part of the uNK signature genes. Overall, these results suggest that uNK, at least in EGFR-WT NSCLC patients, may have a potiental role to support T-cell activation.

我们收集了 12 名 NSCLC 患者的 PBMC 和肿瘤浸润淋巴细胞 (TIL) 样本来进行 scRNA 测序。从TIL结果来看，我们发现EGFR-Mut患者的NK细胞总数比例高于WT患者。然而，EGFR-WT 患者中的 uNK（NK 细胞集合）比例高于 EGFR-Mut 患者。我们进一步建立了一组与CD8T细胞中激活标记物的表达正相关的uNK特征基因。在研究患者 PBMC 的 scRNA-Seq 数据时，NK 细胞表达部分 uNK 特征基因。总体而言，这些结果表明，至少在 EGFR-WT NSCLC 患者中，uNK 可能具有支持 T 细胞激活的潜在作用。